Skip to main content
. 2022 May 12;5:449. doi: 10.1038/s42003-022-03376-y

Fig. 2. β-glucan can protect against mannan-induced psoriasis (MIP).

Fig. 2

MIP was induced in Ncf1-deficient mice with or without co-administration of 1,3-β-glucan (a, b) or 1,6-β-glucan (c, d). Arthritis severity was followed, and spleen weight measured at the end of the experiment at day 8 in (a, b) and day 7 in (c, d). MIP was induced in Ncf1-deficient mice on day 0, and 3 mg of 1,6-β-glucan administered one day later (e). Arthritis severity was followed, and spleens weighted at the end of the experiment on day 9. The number of mice in each group is shown in parentheses. The data in (c) are pooled from two experiments, except the doses of 1 mg and 2 mg which were included only in one experiment. Spleen index was calculated with the data from one experiment. For groups with 1,6-β-glucan alone, N = 8 for arthritis, and N = 4 for spleen weight. Results are presented as mean and error bars represent the SEM. Statistical analyses were performed by Mann–Whitney test and * indicates a comparison between mannan and mannan + 3 mg β-glucan, whereas ^ indicates comparison between mannan and β-glucan in severity graphs. */^P < 0.05; **/^^P < 0.01; and ***P < 0.001.